Retour

Cartesian Therapeutics Announces New Employment Inducement Grant

Stocks Changes in company's own shares

GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to a new employee. On June 3, 2024, the Company issued to this employee an option to purchase 11,000 shares of the Company’s common stock with an exercise price of $36.00, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company’s board of directors. The option vests as to 25% on June 3, 2025, and then in three equal annual installments thereafter such that the option will be fully vested on June 3, 2028. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee’s entry into employment with the Company.

GlobeNewswire Inc. • 06/06/2024 à 13:05:00
Cartesian Therapeutics, Inc. Common Stock
Adresse: 704 QUINCE ORCHARD RD
Code postal: 20878
Ville: GAITHERSBURG
Region: MD
Numéro de telephone: 617-923-1400
Site internet: https://www.cartesiantherapeutics.com
Status: Active
Info de l'entreprise

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

Date de référencement2016-06-22
MarchéStocks
LocaleUS
Echange principalXNAS
TypeCS
DeviseUSD
CIK0001453687
Composite figiBBG001J19Q25
Share Class figiBBG001V0FQQ0
Market Cap277,544,655 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employés38
Share Class Shares Outstanding21380000
Weighted Shares Outstanding21382485
Round Lot100
Date de mise à jour2024-09-07
Stats
Historique
PériodeVarPlus hautPlus bas
1 semaine
-3.59%
14.025
13.545
1 mois
-5.11%
14.76
13.545
3 mois
-63.37%
36.8
13.545
6 mois
-31.94%
21
11.665
1 an
-44.62%
32.1
11.665
3 ans
-44.62%
32.1
11.665
5 ans
-44.62%
32.1
11.665
10 ans
-44.62%
32.1
11.665
Calendrier économique
6 Septembre 2024 (heure UTC) Actuel Précédent Consensus
★
15:30
United States
SEP 03
-27700.000
-32700.000
★
15:30
United States
SEP 03
46100.000
52200.000
★
15:30
United States
SEP 03
-48800.000
-81900.000
★
15:30
United States
SEP 03
-100300.000
-92200.000
★★
15:30
United States
SEP 03
26000.000
21400.000
★
15:30
United States
SEP 03
287600.000
294400.000
★
15:30
United States
SEP 03
177000.000
226700.000
★
15:30
United States
SEP 03
-90500.000
-148500.000
★
15:30
United States
SEP 03
-162000.000
-184300.000
★
15:30
United States
SEP 03
13000.000
17100.000
★
15:30
United States
SEP 03
2300.000
2200.000
★
15:30
United States
★
15:30
United States
★★
15:30
United States
★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:RNAC1240621P00007500 OPASPN Put American 100 7.5 BATO 2024-06-21
O:RNAC1240621P00005000 OPASPN Put American 100 5 BATO 2024-06-21
O:RNAC1240621P00002500 OPASPN Put American 100 2.5 BATO 2024-06-21
O:RNAC1240621C00007500 OCASPN Call American 100 7.5 BATO 2024-06-21
O:RNAC1240621C00005000 OCASPN Call American 100 5 BATO 2024-06-21
O:RNAC1240621C00002500 OCASPN Call American 100 2.5 BATO 2024-06-21
O:RNAC240621P00007500 OPASPS Put American 100 7.5 BATO 2024-06-21
O:RNAC240621P00005000 OPASPS Put American 100 5 BATO 2024-06-21
O:RNAC240621P00002500 OPASPS Put American 100 2.5 BATO 2024-06-21
O:RNAC240621C00007500 OCASPS Call American 100 7.5 BATO 2024-06-21
O:RNAC240621C00005000 OCASPS Call American 100 5 BATO 2024-06-21
O:RNAC240621C00002500 OCASPS Call American 100 2.5 BATO 2024-06-21
O:RNAC2240621P00007500 OPASPN Put American 3 7.5 BATO 2024-06-21
O:RNAC2240621P00005000 OPASPN Put American 3 5 BATO 2024-06-21
O:RNAC2240621P00002500 OPASPN Put American 3 2.5 BATO 2024-06-21
O:RNAC2240621C00007500 OCASPN Call American 3 7.5 BATO 2024-06-21
O:RNAC2240621C00005000 OCASPN Call American 3 5 BATO 2024-06-21
O:RNAC2240621C00002500 OCASPN Call American 3 2.5 BATO 2024-06-21
O:RNAC240517P00007500 OPASPS Put American 100 7.5 BATO 2024-05-17
O:RNAC240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:RNAC240517P00002500 OPASPS Put American 100 2.5 BATO 2024-05-17
O:RNAC240517C00007500 OCASPS Call American 100 7.5 BATO 2024-05-17
O:RNAC240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:RNAC240517C00002500 OCASPS Call American 100 2.5 BATO 2024-05-17
O:RNAC240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:RNAC240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:RNAC240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:RNAC240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:RNAC240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:RNAC240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:RNAC2240419P00007500 OPASPN Put American 3 7.5 BATO 2024-04-19
O:RNAC2240419P00005000 OPASPN Put American 3 5 BATO 2024-04-19
O:RNAC2240419P00002500 OPASPN Put American 3 2.5 BATO 2024-04-19
O:RNAC2240419C00007500 OCASPN Call American 3 7.5 BATO 2024-04-19
O:RNAC2240419C00005000 OCASPN Call American 3 5 BATO 2024-04-19
O:RNAC2240419C00002500 OCASPN Call American 3 2.5 BATO 2024-04-19
O:RNAC240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:RNAC240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:RNAC240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:RNAC240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:RNAC240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:RNAC240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:RNAC1240315P00007500 OPASPN Put American 100 7.5 BATO 2024-03-15
O:RNAC1240315P00005000 OPASPN Put American 100 5 BATO 2024-03-15
O:RNAC1240315P00002500 OPASPN Put American 100 2.5 BATO 2024-03-15
O:RNAC1240315C00007500 OCASPN Call American 100 7.5 BATO 2024-03-15
O:RNAC1240315C00005000 OCASPN Call American 100 5 BATO 2024-03-15
O:RNAC1240315C00002500 OCASPN Call American 100 2.5 BATO 2024-03-15
O:RNAC240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:RNAC240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:RNAC240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:RNAC240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:RNAC240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:RNAC240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:RNAC1240119P00007500 OPASPN Put American 100 7.5 BATO 2024-01-19
O:RNAC1240119P00005000 OPASPN Put American 100 5 BATO 2024-01-19
O:RNAC1240119P00002500 OPASPN Put American 100 2.5 BATO 2024-01-19
O:RNAC1240119C00007500 OCASPN Call American 100 7.5 BATO 2024-01-19
O:RNAC1240119C00005000 OCASPN Call American 100 5 BATO 2024-01-19
O:RNAC240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:RNAC1240119C00002500 OCASPN Call American 100 2.5 BATO 2024-01-19
O:RNAC240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:RNAC240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:RNAC240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:RNAC240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:RNAC240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
Flux d'actualités
News Cartesian Therapeutics
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates - Zacks Investment Research
Cartesian Therapeutics announced positive top-line results from its mid-stage study evaluating lead candidate Descartes-08 in patients with generalized myasthenia gravis. The study achieved its primary endpoint, with 71% of MG patients treated with Descartes-08 showing significant improvements in MG Composite score compared to 25% with placebo.
Zacks Investment Research • Il y a 2 mois
Stocks Financing Agreements
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $130.0 million to the Company, before deducting placement agent fees and other offering expenses. The PIPE financing is expected to close on or about July 3, 2024, subject to satisfaction of customary closing conditions.
GlobeNewswire Inc. • Il y a 2 mois
Health Health
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
Trial to assess outpatient administration without lymphodepleting chemotherapy in patients with SLE Trial to assess outpatient administration without lymphodepleting chemotherapy in patients with SLE
GlobeNewswire Inc. • Il y a 2 mois
News Product / Services Announcement
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically meaningful improvement in MGC score at Month 3 compared to 25% for placebo
GlobeNewswire Inc. • Il y a 2 mois
Stocks Changes in company's own shares
Cartesian Therapeutics Announces New Employment Inducement Grant
GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to a new employee. On June 3, 2024, the Company issued to this employee an option to purchase 11,000 shares of the Company’s common stock with an exercise price of $36.00, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company’s board of directors. The option vests as to 25% on June 3, 2025, and then in three equal annual installments thereafter such that the option will be fully vested on June 3, 2028. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee’s entry into employment with the Company.
GlobeNewswire Inc. • Il y a 3 mois
Health Health
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
Topline data from Phase 2b trial of Descartes-08 in myasthenia gravis remains on track for mid-2024 Topline data from Phase 2b trial of Descartes-08 in myasthenia gravis remains on track for mid-2024
GlobeNewswire Inc. • Il y a 3 mois
Calendar Calendar of Events
Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
GAITHERSBURG, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024, at 3:00 p.m. ET.
GlobeNewswire Inc. • Il y a 3 mois
Stocks Earnings Releases and Operating Results
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Topline data from Phase 2b trial of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis on track for mid-2024
GlobeNewswire Inc. • Il y a 4 mois
News News
Down -30.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (RNAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks Investment Research • Il y a 5 mois
Stocks Changes in company's own shares
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
Proposals approved at Company’s special meeting of stockholders held March 27, 2024 Proposals approved at Company’s special meeting of stockholders held March 27, 2024
GlobeNewswire Inc. • Il y a 5 mois
Voir tous
Actualités liées
Dernières actualités

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT